17.55
+3.72%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Omeros
From its filings with the US Securities and Exchange Commission
Omeros is based in Seattle, Washington and is incorporated in Washington. Its shares trade on Nasdaq under the ticker OMER. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2020, it reported revenue of $73.8m.
Omeros Corporation (“Omeros,” the “Company” or “we”) is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders.
Our complement-targeted product, product candidates, and therapeutic programs are primarily focused on diseases and disorders associated with the lectin and/or alternative pathways of complement. Our lectin pathway program includes inhibitors of mannan-binding lectin-associated serine protease 2 (“MASP-2”) and our alternative pathway program includes inhibitors of mannan-binding lectin-associated serine protease 3 (“MASP-3”).
YARTEMLEA® (narsoplimab-wuug) is the first and only approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”), an often-fatal complication of stem cell transplantation driven by activation of the lectin pathway of complement. YARTEMLEA selectively inhibits MASP-2, the effector enzyme of the lectin pathway, blocking the pathway’s activation while preserving classical and alternative complement functions important for host defense against infection.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 8 Oct 2009
- Employees
- 175
- Website
- omeros.com ↗
- Head office
- 201 ELLIOTT AVENUE WEST, SEATTLE, WA, 98119
- Incorporated in
- WA
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Gregory DemopulosChairman of the Board, President, Chief Executive Officer, since 1994$3.8m
- Mr. David BorgesChief Accounting Officer, Vice President - Finance, Treasurer$627,907
- Dr. George GaitanarisVice President - Science, Chief Scientific Officer
- Mr. Peter CancelmoVice President, General Counsel, Secretary$906,894
- Mr. Peter WilliamsVice President - Human Resources
- Ms. Nadia DacVice President, Chief Commercial Officer
- Dr. Mariana DimitrovaVice President - Chemistry, Manufacturing and Controls
- Mr. David GhesquiereVice President, Chief Business Development Officer
- Dr. Andreas GrauerVice President, Chief Medical Officer
- Dr. Catherine MelfiVice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
- Dr. J. Steven WhitakerVice President - Clinical Development
- Mr. Thomas CableLead Independent Director$159,073
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 33
- Environment
- 35
- Social
- 40
- Governance
- 24
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Omeros Corp has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company has a strong portfolio of innovative drug products. These products have demonstrated positive results in clinical trials, providing a competitive edge in the market. Secondly, Omeros Corp has a dedicated and experienced research and development team. This team continuously works on developing new drugs and improving existing ones, ensuring a pipeline of future products. Thirdly, the company has established strategic partnerships with leading healthcare organizations, allowing for a broader reach and distribution of their drugs.
Weaknesses
- Despite its strengths, Omeros Corp also faces some weaknesses that need to be addressed. One major weakness is the company's dependency on its key drug products. If any of these products face regulatory challenges or fail to meet market expectations, it could significantly impact the company's revenue. Additionally, Omeros Corp has a relatively small market share compared to some of its competitors. This limited market presence increases the vulnerability to market fluctuations and competitive pressures.
Opportunities
- The pharmaceutical industry presents several opportunities for Omeros Corp to capitalize on. Firstly, there is a growing demand for innovative and effective drug therapies worldwide. Omeros Corp can leverage its research capabilities to develop new drugs that address unmet medical needs, thereby capturing a larger market share. Secondly, with the advancements in technology and personalized medicine, there is an opportunity for Omeros Corp to explore partnerships and collaborations in precision medicine. This would enable the company to tailor treatments to individual patients and potentially enhance patient outcomes. Thirdly, expanding into emerging markets presents a significant opportunity for Omeros Corp to tap into new customer bases and diversify its revenue streams.
Threats
- Omeros Corp operates in an industry that is filled with potential threats. Firstly, the pharmaceutical industry is highly regulated, and any changes in regulations or approval processes can impact the company's ability to bring new drugs to market. Additionally, Omeros Corp faces intense competition from both large pharmaceutical companies and smaller biotech firms. This competitive landscape poses a threat to the company's market share and profitability. Furthermore, there is always the risk of intellectual property infringement, as competitors may attempt to replicate Omeros Corp's successful drug products. Finally, global economic instability and fluctuations in currency exchange rates could impact the company's export activities and international sales.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.